Mereo BioPharma Group plc (MREO)
MREO Stock Price Chart
Explore Mereo BioPharma Group plc interactive price chart. Choose custom timeframes to analyze MREO price movements and trends.
MREO Company Profile
Discover essential business fundamentals and corporate details for Mereo BioPharma Group plc (MREO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Apr 2019
Employees
36.00
Website
https://www.mereobiopharma.comCEO
Denise Vera Scots-Knight
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
MREO Financial Timeline
Browse a chronological timeline of Mereo BioPharma Group plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.00, while revenue estimate is $3.70M.
Earnings released on 12 Aug 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $685.71K .
Earnings released on 13 May 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%.
Earnings released on 26 Mar 2025
EPS came in at -$0.01 surpassing the estimated -$0.02 by +50.00%, while revenue for the quarter reached $1.33M , missing expectations by -88.80%.
Earnings released on 12 Nov 2024
EPS came in at -$7.69 falling short of the estimated -$1.36 by -465.44%.
Earnings released on 13 Aug 2024
EPS came in at -$0.02 surpassing the estimated -$0.78 by +97.44%.
Earnings released on 15 May 2024
EPS came in at -$0.01 .
Earnings released on 27 Mar 2024
EPS came in at -$0.01 surpassing the estimated -$0.02 by +44.75%, while revenue for the quarter reached $456.43K .
Earnings released on 17 Nov 2023
EPS came in at -$0.01 , while revenue for the quarter reached $648.81K .
Earnings released on 7 Sept 2023
EPS came in at -$0.03 falling short of the estimated -$0.02 by -37.05%, while revenue for the quarter reached $11.13M .
Earnings released on 27 Jun 2023
EPS came in at -$0.01 , while revenue for the quarter reached $4.41M .
Earnings released on 28 Mar 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +28.87%, while revenue for the quarter reached $1.02M .
Earnings released on 2 Nov 2022
EPS came in at -$0.02 surpassing the estimated -$0.38 by +95.58%, while revenue for the quarter reached $746.79K .
Earnings released on 30 Jun 2022
EPS came in at -$0.05 .
Earnings released on 1 Apr 2022
EPS came in at $0.00 surpassing the estimated -$4.50 by +100.04%.
Earnings released on 31 Mar 2022
EPS came in at -$0.03 , while revenue for the quarter reached $606.46K .
Earnings released on 8 Nov 2021
EPS came in at $0.00 surpassing the estimated -$2.50 by +100.04%, while revenue for the quarter reached $416.83K .
Earnings released on 30 Jun 2021
EPS came in at $0.04 , while revenue for the quarter reached $69.97M .
Earnings released on 31 Mar 2021
EPS came in at $0.03 , while revenue for the quarter reached $34.72M .
Earnings released on 31 Mar 2021
EPS came in at -$0.21 falling short of the estimated -$0.07 by -207.45%.
Earnings released on 29 Sept 2020
EPS came in at -$0.14 surpassing the estimated -$0.50 by +71.29%.
MREO Stock Performance
Access detailed MREO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.